MX2011012234A - Plasmido libre de antibiotico. - Google Patents
Plasmido libre de antibiotico.Info
- Publication number
- MX2011012234A MX2011012234A MX2011012234A MX2011012234A MX2011012234A MX 2011012234 A MX2011012234 A MX 2011012234A MX 2011012234 A MX2011012234 A MX 2011012234A MX 2011012234 A MX2011012234 A MX 2011012234A MX 2011012234 A MX2011012234 A MX 2011012234A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- formulations
- drugless plasmids
- drugless
- plasmids
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 abstract 6
- 238000009472 formulation Methods 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/73—Expression systems using phage (lambda) regulatory sequences
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona un método para mantener un plásmido de bacteria gram negativa sin el uso de la presión de selección de antibiótico. Además, la invención se relaciona a los plásmidos sin fármaco producidos, que incluyen plásmidos sin fármaco que contienen un gen heterólogo. La invención también proporciona formulaciones y/o composiciones que comprenden los plásmidos sin fármaco que comprenden un gen heterólogo, formulaciones y/o composiciones que comprenden una proteína o un inmunógeno expresado usando los plásmidos sin fármaco, y métodos para administrar tales formulaciones y/o composiciones a un hospedero. La invención se relaciona a bacterias gram negativas que contienen los plásmidos sin fármaco.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18075509P | 2009-05-22 | 2009-05-22 | |
| PCT/US2010/035979 WO2010135742A1 (en) | 2009-05-22 | 2010-05-24 | Antibiotic-free plasmid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011012234A true MX2011012234A (es) | 2012-03-07 |
Family
ID=42342694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012234A MX2011012234A (es) | 2009-05-22 | 2010-05-24 | Plasmido libre de antibiotico. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9217153B2 (es) |
| EP (2) | EP2432884B1 (es) |
| JP (2) | JP5918125B2 (es) |
| KR (1) | KR101719833B1 (es) |
| AU (1) | AU2010249325B2 (es) |
| BR (1) | BRPI1011048B1 (es) |
| CA (1) | CA2761964C (es) |
| DK (1) | DK2432884T3 (es) |
| ES (1) | ES2600612T3 (es) |
| HR (1) | HRP20161397T1 (es) |
| HU (1) | HUE031597T2 (es) |
| LT (1) | LT2432884T (es) |
| MX (1) | MX2011012234A (es) |
| NZ (1) | NZ596453A (es) |
| PL (1) | PL2432884T3 (es) |
| PT (1) | PT2432884T (es) |
| RU (1) | RU2548809C2 (es) |
| SI (1) | SI2432884T1 (es) |
| WO (1) | WO2010135742A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5966018B2 (ja) | 2011-12-21 | 2016-08-10 | バイオネット−エイジア，カンパニー・リミテッド | 改変ボルデテラ・パータシス株 |
| CN106170551B (zh) * | 2013-12-16 | 2020-01-07 | 财团法人农业科技研究院 | 生产不耐热肠毒素b亚单位的质粒、方法及其套组 |
| CN106715681B (zh) * | 2014-07-25 | 2021-08-24 | R·P·谢勒科技有限责任公司 | 用于生产蛋白质的经改进的宿主细胞 |
| EP3799882A1 (en) | 2016-11-01 | 2021-04-07 | Novo Nordisk A/S | Tolerogenic dna vaccine |
| RU2705252C1 (ru) * | 2018-06-08 | 2019-11-06 | Селл энд Джин Терапи Лтд | Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген CFTR, или NOS1, или AQ1, или AQ3, или AQ5, для лечения заболеваний, связанных с необходимостью повышения уровня экспрессии этих целевых генов, способ его получения и использования, штамм Escherichia coli SCS110-AF/VTvaf17-CFTR, или Escherichia coli SCS110-AF/VTvaf17-NOS1, или Escherichia coli SCS110-AF/VTvaf17-AQ1, или Escherichia coli SCS110-AF/VTvaf17-AQ3, или Escherichia coli SCS110-AF/VTvaf17-AQ5, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
| WO2020050744A1 (en) * | 2018-09-04 | 2020-03-12 | Obschestvo S Ogranichennoi Otvetstvennostju "Allel Tsentr Innovatsionnykh Biotekhnology" | Gene therapy based on vector vtvaf17 |
| RU2712838C1 (ru) * | 2018-09-04 | 2020-01-31 | Генетик Диагностик Энд Терапи 21 Лтд | Генотерапевтический ДНК-вектор GDTT1.8NAS12, способ его получения, штамм Escherichia coli JM110-NAS, способ его получения, штамм Escherichia coli JM110-NAS/GDTT1.8NAS12, несущий генотерапевтический ДНК-вектор GDTT1.8NAS12, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
| RU2705256C1 (ru) * | 2018-09-05 | 2019-11-06 | Общество С Ограниченной Ответственностью "Прорывные Инновационные Технологии" | Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов SKI, TGFB3, TIMP2, FMOD для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-SKI или Escherichia coli SCS110-AF/VTvaf17-TGFB3 или Escherichia coli SCS110-AF/VTvaf17-TIMP2 или Escherichia coli SCS110-AF/VTvaf17-FMOD, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
| RU2730664C2 (ru) * | 2018-12-27 | 2020-08-24 | Селл энд Джин Терапи Лтд | Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов ANG, ANGPT1, VEGFA, FGF1, HIF1α, HGF, SDF1, KLK4, PDGFC, PROK1, PROK2 для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-ANG, или Escherichia coli SCS110-AF/VTvaf17-ANGPT1, или Escherichia coli SCS110-AF/VTvaf17-VEGFA, или Escherichia coli SCS110-AF/VTvaf17-FGF1, или Escherichia coli SCS110-AF/VTvaf17-HIF1α, или Escherichia coli SCS110-AF/VTvaf17-HGF, или Escherichia coli SCS110-AF/VTvaf17-SDF1, или Escherichia coli SCS110-AF/VTvaf17-KLK4, или Escherichia coli SCS110-AF/VTvaf17-PDGFC, или Escherichia coli SCS110-AF/VTvaf17-PROK1, или Escherichia coli SCS110-AF/VTvaf17-PROK2, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
| RU2715314C1 (ru) * | 2019-01-25 | 2020-02-26 | Селл энд Джин Терапи Лтд | Генотерапевтический ДНК-вектор VTvaf17-Act1-Cas9 на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген Cas9, для гетерологичной экспрессии этого целевого гена в клетках растений при геномном редактировании растений, способ получения и применения генотерапевтического ДНК-вектора, штамм Escherichia coli SCS110-AF/VTvaf17-Act1-Cas9, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
| US11279745B2 (en) | 2019-04-26 | 2022-03-22 | Novo Nordisk A/S | Tolerogenic DNA vaccine |
| US20230203536A1 (en) | 2020-05-28 | 2023-06-29 | Consejo Superior De Investigaciones Científicas (Csic) | Coronavirus rna replicons and use thereof as vaccines |
| EP4019539A1 (en) * | 2020-12-22 | 2022-06-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Recombinant bacterium and uses thereof |
| US20250018027A1 (en) | 2021-11-26 | 2025-01-16 | Consejo Superior De Investigaciones Científicas | Coronavirus derived rna replicons and their use as vaccines |
| JPWO2024096123A1 (es) * | 2022-11-04 | 2024-05-10 | ||
| CN118374547A (zh) * | 2023-01-13 | 2024-07-23 | 上海吉量医药工程有限公司 | 一种无抗微质粒及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4506013A (en) * | 1980-10-03 | 1985-03-19 | Eli Lilly And Company | Stabilizing and selecting recombinant DNA host cells |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5059529A (en) * | 1984-08-27 | 1991-10-22 | Bio-Technology General Corp. | Stabilized expression vectors containing λPL promoter and the gene for the cI434 repressor, plasmids containing the vectors, hosts containing the plasmids and related methods |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| IE872455L (en) | 1986-09-12 | 1988-03-12 | Lanstrase Ltd | Improved recombinant expression |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
| US5300431A (en) * | 1991-02-26 | 1994-04-05 | E. I. Du Pont De Nemours And Company | Positive selection vector for the bacteriophage P1 cloning system |
| CA2214029A1 (en) | 1995-04-25 | 1996-10-31 | Magda Marquet | Single-vial formulations of dna/lipid complexes |
| US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| EP0963439B1 (en) * | 1997-02-19 | 2007-04-11 | Enol Energy Inc. | Genetically modified cyanobacteria for the production of ethanol |
| AU6511000A (en) * | 1999-08-02 | 2001-02-19 | Baylor College Of Medicine | Novel vectors and system for selectable targeted integration of transgenes into a chromosome without antibiotic resistance markers |
| GB0211459D0 (en) * | 2002-05-18 | 2002-06-26 | Cobra Therapeutics Ltd | Plasmid stabilisation in vivo |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| TWI311152B (en) * | 2004-09-17 | 2009-06-21 | Boehringer Ingelheim Rcv Gmbh & Co K | Host-vector system for antibiotic-free cole1 plasmid propagation |
| RU2312146C1 (ru) * | 2006-03-30 | 2007-12-10 | Николай Викторович Равин | Вектор на основе репликона бактериофага n15 и рекомбинантный вектор для регулируемой экспрессии целевого гена в клетках escherichia coli, штамм escherichia coli, обеспечивающий возможность регуляции числа копий вектора, и система экспрессии |
-
2010
- 2010-05-24 WO PCT/US2010/035979 patent/WO2010135742A1/en not_active Ceased
- 2010-05-24 PL PL10720510T patent/PL2432884T3/pl unknown
- 2010-05-24 KR KR1020117030800A patent/KR101719833B1/ko active Active
- 2010-05-24 PT PT107205106T patent/PT2432884T/pt unknown
- 2010-05-24 LT LTEP10720510.6T patent/LT2432884T/lt unknown
- 2010-05-24 ES ES10720510.6T patent/ES2600612T3/es active Active
- 2010-05-24 EP EP10720510.6A patent/EP2432884B1/en active Active
- 2010-05-24 BR BRPI1011048A patent/BRPI1011048B1/pt active IP Right Grant
- 2010-05-24 RU RU2011152377/10A patent/RU2548809C2/ru active
- 2010-05-24 CA CA2761964A patent/CA2761964C/en active Active
- 2010-05-24 AU AU2010249325A patent/AU2010249325B2/en active Active
- 2010-05-24 EP EP16164124.6A patent/EP3124613B1/en active Active
- 2010-05-24 HU HUE10720510A patent/HUE031597T2/en unknown
- 2010-05-24 SI SI201031305A patent/SI2432884T1/sl unknown
- 2010-05-24 US US12/786,186 patent/US9217153B2/en active Active
- 2010-05-24 JP JP2012512086A patent/JP5918125B2/ja active Active
- 2010-05-24 DK DK10720510.6T patent/DK2432884T3/en active
- 2010-05-24 NZ NZ596453A patent/NZ596453A/xx unknown
- 2010-05-24 HR HRP20161397TT patent/HRP20161397T1/hr unknown
- 2010-05-24 MX MX2011012234A patent/MX2011012234A/es active IP Right Grant
-
2015
- 2015-08-26 JP JP2015166767A patent/JP2015221050A/ja active Pending
- 2015-11-03 US US14/930,710 patent/US10487334B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2432884A1 (en) | 2012-03-28 |
| AU2010249325B2 (en) | 2014-12-18 |
| ES2600612T3 (es) | 2017-02-10 |
| BRPI1011048B1 (pt) | 2019-01-29 |
| US9217153B2 (en) | 2015-12-22 |
| LT2432884T (lt) | 2016-11-10 |
| EP3124613B1 (en) | 2020-03-11 |
| KR20120016661A (ko) | 2012-02-24 |
| HRP20161397T1 (hr) | 2016-12-16 |
| JP2015221050A (ja) | 2015-12-10 |
| RU2548809C2 (ru) | 2015-04-20 |
| CA2761964A1 (en) | 2010-11-25 |
| DK2432884T3 (en) | 2016-08-22 |
| CN102482679A (zh) | 2012-05-30 |
| PT2432884T (pt) | 2016-10-06 |
| RU2011152377A (ru) | 2013-06-27 |
| SI2432884T1 (sl) | 2016-11-30 |
| CA2761964C (en) | 2018-11-27 |
| KR101719833B1 (ko) | 2017-03-24 |
| US20160312231A1 (en) | 2016-10-27 |
| EP3124613A1 (en) | 2017-02-01 |
| WO2010135742A1 (en) | 2010-11-25 |
| NZ596453A (en) | 2013-09-27 |
| JP5918125B2 (ja) | 2016-05-18 |
| EP2432884B1 (en) | 2016-08-03 |
| HUE031597T2 (en) | 2017-07-28 |
| JP2012527249A (ja) | 2012-11-08 |
| US20100298419A1 (en) | 2010-11-25 |
| US10487334B2 (en) | 2019-11-26 |
| AU2010249325A1 (en) | 2011-12-08 |
| PL2432884T3 (pl) | 2017-01-31 |
| BRPI1011048A2 (pt) | 2016-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011012234A (es) | Plasmido libre de antibiotico. | |
| MX2010002867A (es) | Cepas de micoplasma atenuadas vivas. | |
| MY193665A (en) | Recombinant microorganisms and uses therefor | |
| TW200806316A (en) | Yeast-based vaccine for inducing an immune response | |
| CA2830786C (en) | Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a | |
| DK2566507T3 (da) | Biokonjugatvacciner med kapselformige grampositive bakterier | |
| MX366793B (es) | Metodos para preparar oxazolidinonas y composiciones que las contienen. | |
| WO2007024941A3 (en) | Polyvalent vaccine | |
| WO2007104451A8 (en) | Live attenuated bordetella strains as a single dose vaccine against whooping cough | |
| WO2013006055A8 (en) | A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium | |
| MY165831A (en) | Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with a improved immunogenicity | |
| MX2008011247A (es) | Vacuna de micoplasma hyopneumoniae. | |
| MX349119B (es) | Vacuna de virus de dengue inactivado. | |
| GEP20115293B (en) | Isolated extract of walnuts, process for its obtaining and its use | |
| MX2012003426A (es) | Bacterias gram-negativas modificadas para su uso como vacunas. | |
| EP2574170A4 (en) | IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS | |
| WO2010132112A3 (en) | Immunogenic compositions against tuberculosis | |
| MX2010002866A (es) | Capas de mycoplasma gallisepticum atenuadas. | |
| MX2007007291A (es) | Procedimiento de produccion eficiente novedoso para polisacaridos capsulares de bacterias gram positivas patogenas mediante expresion heterologa y secrecion de polisacaridos complejos en bacterias gram positivas no patogenas, no invasivas. | |
| WO2022103929A3 (en) | Nucleic acids, proteins, and vaccines of sars-cov-2 | |
| WO2017139708A8 (en) | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) | |
| NZ589981A (en) | Cattle vaccines comprising a disrupted M. bovis bacterium | |
| WO2005092372A3 (en) | Modified bacillus anthracis vaccine compositions and methods of use thereof | |
| MY159439A (en) | Method for producing glucosidase, enzyme composition, and method for hydrolyzing biomass | |
| AU2003255275A1 (en) | Improved anthrax vaccines and delivery methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |